Otros idiomas Vigil Neuroscience, Inc.

Acciones

VIGL

US92673K1088

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 31/05/2024			Varia. Cinco días.	Varia. 1 de enero.
3,18 ^USD	-0,62 %		-12,40 %	-5,92 %

07/05	Vigil Neuroscience, Inc. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI
17/04	Vigil Neuroscience, Inc. Presenta los hallazgos clave de los estudios Illuminate & Ignite en ALSP en la Reunión Anual 2024 de la Academia Americana de Neurología	CI

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Vigil Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting	17/04
VIGIL NEUROSCIENCE, INC. : Wedbush maintient sa recommandation à l'achat	26/03
Vigil Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Vigil Neuroscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/03
Vigil Neuroscience Names Petra Kaufmann Chief Medical Officer	20/03
Vigil Neuroscience, Inc. Announces Executive Changes	20/03
Transcript : Vigil Neuroscience, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07:30 AM	11/01
VIGIL NEUROSCIENCE, INC. : Morgan Stanley n'est plus neutre mais vendeur	19/12
Vigil Neuroscience Reports Positive Interm Results for Treatment of Axonal Spheroids and Pigmented Glia	16/11
Transcript : Vigil Neuroscience, Inc. - Special Call	16/11
Vigil Neuroscience, Inc. Reports Positive Interim Data from Phase 2 Ignite Proof-Of-Concept Clinical Trial Evaluating Iluzanebart as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE	16/11
Vigil Neuroscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
VIGIL NEUROSCIENCE, INC. : JMP Securities favorable sur le dossier	18/10/23
Vigil Neuroscience Shares Rise After First Participant Dosed in Phase 1 Trial of Potential Alzheimer's Disease Treatment	17/10/23
Vigil Neuroscience, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating Vv-3927, a Small Molecule Trem2 Agonist, for Potential Treatment of Alzheimer's Disease	17/10/23
Vigil Neuroscience, Inc Provides an Update on the Small Molecule TREM2 Agonist, VG-3927	12/10/23
Vigil Says Orphan Drug Designation Application for Proposed Leukoencephalopathy Therapy Secured European Positive Opinion	26/09/23
Vigil Neuroscience, Inc. Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for Vgl101 for the Treatment of ALSP	26/09/23
Transcript : Vigil Neuroscience, Inc. - Special Call	13/09/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Vigil Neuroscience, Inc.

Acciones

VIGL

US92673K1088

Otros idiomas

Filtros